Top

Annals of Hematology

Published in:

01-03-2021 | Myelodysplastic Syndrome | Letter to the Editor

Compassionate use of glasdegib in combination with low-dose cytarabine for relapsed, refractory acute myeloid leukemia or high-risk myelodysplastic syndrome

Authors: Márcio Tavares, Sérgio Chacim, José Mário Mariz

Published in: Annals of Hematology | Issue 3/2021

Excerpt

Dear Editor, …

Queiroz KC, Ruela-de-Sousa RR, Fuhler GM, Aberson HL, Ferreira CV, Peppelenbosch MP et al (2010) Hedgehog signaling maintains chemoresistance in myeloid leukemic cells. Oncogene 29(48):6314–6322. https://doi.org/10.1038/onc.2010.375CrossRefPubMed

Fukushima N, Minami Y, Kakiuchi S, Kuwatsuka Y, Hayakawa F, Jamieson C et al (2016) Small-molecule Hedgehog inhibitor attenuates the leukemia-initiation potential of acute myeloid leukemia cells. Cancer Sci 107(10):1422–1429. https://doi.org/10.1111/cas.13019CrossRefPubMedPubMedCentral

Norsworthy KJ, By K, Subramaniam S, Zhuang L, Del Valle PL, Przepiorka D et al (2019) FDA Approval Summary: Glasdegib for newly diagnosed acute myeloid leukemia. Clin Cancer Res 25(20):6021–6025. https://doi.org/10.1158/1078-0432.ccr-19-0365CrossRefPubMed

Sallman DA, Komrokji RS, Sweet KL, Mo Q, McGraw KL, Duong VH et al (2019) A phase 2 trial of the oral smoothened inhibitor glasdegib in refractory myelodysplastic syndromes (MDS). Leuk Res 81:56–61. https://doi.org/10.1016/j.leukres.2019.03.008CrossRefPubMedPubMedCentral

Zeidan AM, Smith BD, Carraway HE, Gojo I, De Zern A, Gore SD (2017) A phase 2 trial of high dose lenalidomide in patients with relapsed/refractory higher-risk myelodysplastic syndromes and acute myeloid leukaemia with trilineage dysplasia. Brit J Haematol 176(2):241–247. https://doi.org/10.1111/bjh.14407CrossRef

DiNardo CD, Rausch CR, Benton C, Kadia T, Jain N, Pemmaraju N et al (2018) Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies. Am J Hematol 93(3):401–407. https://doi.org/10.1002/ajh.25000CrossRefPubMed

Kubasch AS, Schulze F, Giagounidis A, Götze KS, Krönke J, Sockel K et al (2020) Single agent talacotuzumab demonstrates limited efficacy but considerable toxicity in elderly high-risk MDS or AML patients failing hypomethylating agents. Leukemia 34(4):1182–1186. https://doi.org/10.1038/s41375-019-0645-zCrossRefPubMed

Schlenk RF, Frech P, Weber D, Brossart P, Horst HA, Kraemer D et al (2017) Impact of pretreatment characteristics and salvage strategy on outcome in patients with relapsed acute myeloid leukemia. Leukemia 31(5):1217–1220. https://doi.org/10.1038/leu.2017.22CrossRefPubMedPubMedCentral

Duong VH, Lin K, Reljic T, Kumar A, Al Ali NH, Lancet JE et al (2013) Poor outcome of patients with myelodysplastic syndrome after azacitidine treatment failure. Clin Lymphoma Myeloma Leuk 13(6):711–715. https://doi.org/10.1016/j.clml.2013.07.007CrossRefPubMed

10.

Cortes JE, Heidel FH, Hellmann A, Fiedler W, Smith BD, Robak T et al (2019) Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome. Leukemia 33(2):379–389. https://doi.org/10.1038/s41375-018-0312-9CrossRefPubMed

Title: Compassionate use of glasdegib in combination with low-dose cytarabine for relapsed, refractory acute myeloid leukemia or high-risk myelodysplastic syndrome
Authors: Márcio Tavares
Sérgio Chacim
José Mário Mariz
Publication date: 01-03-2021
Publisher: Springer Berlin Heidelberg
Keywords: Myelodysplastic Syndrome
Acute Myeloid Leukemia
Published in: Annals of Hematology / Issue 3/2021
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI: https://doi.org/10.1007/s00277-020-04291-0

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24 to hear Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Compassionate use of glasdegib in combination with low-dose cytarabine for relapsed, refractory acute myeloid leukemia or high-risk myelodysplastic syndrome

Excerpt

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 3/2021

Post-transplant ferritin level predicts outcomes after allogeneic hematopoietic stem cell transplant, independent from pre-transplant ferritin level

Building a network of TP53 and IGHV testing reference centers across Spain: the Red53 initiative

Antimicrobial prophylaxis in patients with immune thrombocytopenia treated with rituximab: a retrospective multicenter analysis

A rare cause of respiratory failure in acute myeloid leukaemia patient

Novel tumour–infiltrating lymphocyte-related risk stratification based by flow cytometry for patients with de novo angioimmunoblastic T cell lymphoma

Hemolytic crisis in a patient treated with eculizumab for paroxysmal nocturnal hemoglobinuria possibly triggered by SARS-CoV-2 (COVID-19): a case report

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page